News

2017

April 11, 2017
Bristol-Myers Squibb and Apexigen, Inc. Announce Clinical Collaboration to Evaluate Opdivo (nivolumab) in Combination with APX005M in Advanced Solid Tumors

March 21, 2017
Phase 1/2 Clinical Trial of Apexigen’s APX005M in Combination with Pembrolizumab (Keytruda®) Opens for Metastatic Melanoma Patients

March 16, 2017
Apexigen Receives Clinical Development Milestone Payment under Collaboration Agreement

2016

April 13, 2016
Apexigen to Present Data on Its Novel Immuno-Oncology Program APX005M at Upcoming Cancer Conferences

2015

November 17, 2015
Apexigen Presents Positive Data for APX005M in Podium Presentation at Immune Checkpoint Inhibitors (ICI) Europe

November 06, 2015
Apexigen Presents Preclinical Data from Novel Immuno-Oncology Candidate APX005M at SITC 2015 Meeting

June 22, 2015
3SBio Acquires Global Rights to Anti-TNF mAb Acquisition expands international product pipeline

June 16, 2015
Apexigen Doses First Patient in Phase 1 Clinical Trial of Its Immuno-oncology Therapeutic Antibody APX005M

May 06, 2015
Apexigen Selected to Present at Cavendish Global Health Impact Forum

2013-14

October 15, 2014
Apexigen Strengthens its Management Team with Additions of Vice President, Clinical Development and Vice President, Finance

Apexigen ranked #4 among US Life Science Start-up Companies by BioSpace (pdf)

October 18, 2013
Apexigen listed in the Top 20 of the 2013 Biotech Start-up Class of 2013 by Xconomy (pdf)

August 6, 2013
Apexigen Secures $20 Million Series A1 Financing

2010-12

December 5, 2012
Boehringer Ingelheim and Apexigen sign manufacturing agreement for process development and early stage clinical supply

November 11, 2012
Apexigen Announces Initiation of Clincal Trials by Its Partner, Simcere Pharmaceutical Group

August 15, 2012
Apexigen Announces the Filing of an IND by its Partner, 3SBio

April 2012
Apexigen Inc. is Using Antibodies Derived from Rabbits to Develop Therapies in Cancer and Inflammatory Disease (pdf)

March 6, 2012
Apexigen and Shanghai Duyiwei Biotechnology Co. Ltd Sign a License and Collaboration Agreement to Develop and Commercialize APX004

March 11, 2011
Apexigen Announces the Filing by its Partner, Simcere Pharmaceutical Group, of First IND

December 7, 2010
Apexigen, Inc. Announces Collaboration for Antibody Discovery

November 22, 2010
BioCentury: Emerging Company Profile - Apexigen: rAbbits hop rodents (pdf)